Current targeting strategies for genetic vectors imply the creation of a
specific vector for every targeted receptor, which is time-consuming and
expensive. Therefore, the development of a universal vector system whose
surface can specifically bind molecules to provide efficient targeting is of
particular interest. In this study, we propose a new approach in creating
targeted vectors based on the genome of human adenovirus serotype 5 carrying
the modified gene of the capsid protein pIX (Ad5-EGFP-pIX-ER): recombinant
pseudoadenoviral nanoparticles (RPANs). The surfaces of such RPANs are able to
bind properly modified chimeric nanoantibodies that specifically recognize a
particular target antigen (carcinoembryonic antigen (CEA)) with high affinity.
The efficient binding of nanoantibodies (aCEA-RE) to the RPAN capsid surfaces
has been demonstrated by ELISA. The ability of the constructed vector to
deliver target genes has been confirmed by experiments with the tumor cell
lines A549 and Lim1215 expressing CEA. It has been shown that Ad5-EGFP-pIX-ER
carrying aCEA-RE on its surface penetrates into the tumor cell lines A549 and
Lim1215 via the CAR-independent pathway three times more efficiently than
unmodified RPAN and Ad5-EGFP-pIX-ER without nanoantibodies on the capsid
surface. Thus, RPAN Ad5-EGFP-pIX-ER is a universal platform that may be useful
for targeted gene delivery in specific cells due to
“nanoantibody–modified RPAN” binding.
Purpose - to study particular properties of the course of the infection among hospitalizedchildren depending on the nature of their treatment provided in pre-hospitalizationperiod in order to improve the results of treatment of children with COVID-19.Material and methods. In a random sample 263 children with COVID-19, admittedto the Department of infectious diseases of the Regional Children's Clinical Hospitalof Chernivtsi, have been examined. The first clinical group includes 68 patients thatreceived antiviral treatment as a part of symptomatic therapy (average age 6,5 ± 0,74years, male ratio 54,4%), and the comparison group - 195 children that did not receiveantiviral activity treatment (average age 6,4 ± 0,41 years, male ratio 50,8%).Results. Most patients with COVID-19 presented signs of moderate to severe medicalstate when admitted to hospital. Patients that did not receive any antiviral therapy in thepre-hospitalization period showed delayed body temperature normalization response (onaverage on the 5th day of the treatment) and, starting from the day 10 of hospitalization,experienced elevated body temperature again caused by infectious and inflammatoryprocess as a result of COVID-19 complications. Changes concerning hemostasisinclude an increase of absolute count of platelets in the blood, reduction in plasmarecalcification time and increase of plasma D-dimer levels (p <0,05). Administration ofantiviral therapy to the children with Covid-19 in the outpatient setting is accompaniedwith absolute risk reduction of a positive PCR test 25% on the 14th day of the disease.Conclusions. Therefore, administration of antiviral therapy to the children with Covid-19in the outpatient setting is characterized with slightly faster temperature normalizationresponse, better clinical signs, virus elimination (minimization of the possibility of apositive PCR test 25%), as well as less excessive hypercoagulable disorder.
The study basing on examination of 102 children with bronchial asthma defines indices of inflammatory activity in the airways and sets the diagnostic value of these indices as tests for verification exercise-induced bronchial asthma. The children with no signs of exercise-induced asthma compared to patients having them, were shown to experience some changes in the exhaled breath condensate, indicating a higher activity of inflammation in the airways. The content of nitrogen monoxide metabolites less than 50 mcmol/L or markers of proteolytic activity by azocol lysis less than 0.2 ml/hour in pulmonary expiration products increase the chances of having exercise-induced bronchial asthma phenotype with these tests sensitivity within 66.7-75.7%.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.